Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026
See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.
Pharma & Biotech
Pharma & Biotech
What Actuate Therapeutics, Inc.’s oral formulation push means for pancreatic cancer drug development economics
Actuate Therapeutics, Inc. is advancing oral elraglusib after FDA IND clearance. Discover what this means for pancreatic cancer economics.
Pharma & Biotech
Theriva Biologics leverages FDA and EMA feedback to optimize VCN-01 pivotal trial
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Explore trial design, dosing strategy, and risks.
Pharma & Biotech
Phanes’ spevatamig shows 40% response rate in mPDAC: How it compares to GnP standard
Phanes’ spevatamig + chemo combo shows 40% ORR in mPDAC. Find out why this bispecific antibody may change frontline pancreatic cancer treatment.